Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma

被引：0

作者：

Shao, Weilin ^{[1
]}

Feng, Yan ^{[1
]}

Huang, Jin ^{[1
]}

Li, Tingyu ^{[3
]}

Gao, Shengguai ^{[3
]}

Yang, Yihao ^{[1
]}

Li, Dongqi ^{[1
]}

Yang, Zuozhang ^{[1
]}

Yao, Zhihong ^{[1
,2
]}

机构：

[1] Kunming Med Univ, Yunnan Canc Hosp, Bone & Soft Tissue Tumours Res Ctr Yunnan Prov, Yunnan Canc Ctr,Affiliated Hosp 3,Dept Orthopaed, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[2] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Affiliated Hosp 3,Dept Canc,Res Inst, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China

[3] Kunming Med Univ, Clin Oncol Inst, Kunming 650500, Yunnan, Peoples R China

来源：

OPEN LIFE SCIENCES | 2024年 / 19卷 / 01期

基金：

美国国家科学基金会;

关键词：

osteosarcoma; PI3K/AKT/mTOR; ncRNAs; biomarkers; therapeutic targets; PROMOTES CELL-PROLIFERATION; SIGNALING PATHWAY; NONCODING RNA; CISPLATIN RESISTANCE; DOWN-REGULATION; TUMOR PROGRESSION; CIRCULAR RNAS; UP-REGULATION; GROWTH; INVASION;

D O I：

10.1515/biol-2022-0936

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, and is characterized by high heterogeneity, high malignancy, easy metastasis, and poor prognosis. Recurrence, metastasis, and multidrug resistance are the main problems that limit the therapeutic effect and prognosis of OS. PI3K/AKT/mTOR signaling pathway is often abnormally activated in OS tissues and cells, which promotes the rapid development, metastasis, and drug sensitivity of OS. Emerging evidence has revealed new insights into tumorigenesis through the interaction between the PI3K/AKT/mTOR pathway and non-coding RNAs (ncRNAs). Therefore, we reviewed the interactions between the PI3K/AKT/mTOR pathway and ncRNAs and their implication in OS. These interactions have the potential to serve as cancer biomarkers and therapeutic targets in clinical applications.

引用

页数：14

共 50 条

[41] The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Monsalves, Eric
Juraschka, Kyle
Tateno, Toru
Agnihotri, Sameer
Asa, Sylvia L.
Ezzat, Shereen
Zadeh, Gelareh
ENDOCRINE-RELATED CANCER, 2014, 21 (04) : R331 - R344
[42] Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
R. Reilly
M. S. Mroz
E. Dempsey
K. Wynne
S. J. Keely
E. F. McKone
C. Hiebel
C. Behl
J. A. Coppinger
Scientific Reports, 7
[43] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
Welker, Mark E.
Kulik, George
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091
[44] The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
Sun, K.
Luo, J.
Guo, J.
Yao, X.
Jing, X.
Guo, F.
OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (04) : 400 - 409
[45] Targeting the PI3K/Akt/mTOR pathway for cancer prevention.
Dennis, PA
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2800S - 2801S
[46] The Role of the PI3K/AKT/mTOR Signalling Pathway in Male Reproduction
Deng, Chun-Yan
Lv, Mei
Luo, Bin-Han
Zhao, Si-Ze
Mo, Zhong-Cheng
Xie, Yuan-Jie
CURRENT MOLECULAR MEDICINE, 2021, 21 (07) : 539 - 548
[47] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, Seiji
Kuroda, Hiromasa
Takahashi, Ryoko
Sasano, Tomoyuki
GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
[48] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
Justin Cidado
Ben Ho Park
Journal of Mammary Gland Biology and Neoplasia, 2012, 17 : 205 - 216
[49] The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
Su, Hengchuan
Gu, Yanyun
Li, Fengying
Wang, Qidi
Huang, Baoxing
Jin, Xiaolong
Ning, Guang
Sun, Fukang
PLOS ONE, 2013, 8 (04):
[50] Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, Jiri, Jr.
Janku, Filip
PHARMACOLOGY & THERAPEUTICS, 2014, 142 (02) : 164 - 175

← 1 2 3 4 5 →